Skip to main content

New Products

  • FDA advisory committee recommends approval for Takeda's vedolizumab

    DEERFIELD, Ill. — An expert panel at the Food and Drug Administration has given a thumbs-up to an experimental drug made by Takeda Pharmaceutical Co. for treating ulcerative colitis and Crohn's disease, the drug maker said.

  • BioElectronics gains distribution deal with U.K.'s Boots on ActiPatch Pain Therapy products

    FREDERICK, Md. — BioElectronics on Monday announced that Boots will be selling its ActiPatch Pain Therapy products in select stores for back, knee and musculoskeletal ailments.  

    The ActiPatch provides pain management therapy for common musculoskeletal complaints through duration pulsed electromagnetic therapy in a small device designed for personal extended use.

  • FDA allows emergency use of still-unapproved vaccine against deadly meningitis amid Princeton University outbreak

    CAMBRIDGE, Mass. — Swiss drug maker Novartis is providing a vaccine to Princeton University amid an outbreak of potentially fatal meningitis that has affected at least eight students, the university said Monday.

  • Teva launches imiquimod cream

    NORTH WALES, Pa. — Teva Pharmaceutical Industries' U.S. subsidiary has launched a generic drug for treating warts and skin lesions, the company said.

    Teva Pharmaceuticals announced the launch and availability of imiquimod cream, a generic version of Medicis Pharmaceutical Corp.'s Aldara.

    The drug is used to treat external genital and rectal warts, certain types of actinic keratosis and basal cell carcinoma. Various versions of the drug had sales of about $244 million in 2011, according to IMS Health.

     

  • Actress Binky Felstead to appear in new Rimmel London campaign in U.K., Ireland

    LONDON — Rimmel London has tapped Binky Felstead to star in its new Sunshimmer advertising campaign in the United Kingdom and Ireland.  

    The award-winning star of E4's show, “Made in Chelsea,” will appear in Sunshimmer's advertising campaign from February 2014.

  • Newly approved hepatitis C treatment by Gilead Sciences said to offer major advance in treatment

    FOSTER CITY, Calif. — The Food and Drug Administration has approved a new drug for hepatitis C made by Gilead Sciences, the drug maker said Friday.

  • Mylan launches cabergoline tablets

    PITTSBURGH — Mylan has launched a generic drug for treating a condition that causes heightened levels of the protein prolactin in the blood, the company said Thursday.

    Mylan announced the launch of cabergoline tablets in the 0.5-mg strength, used for treating hyperprolactinemic disorders.

    Various versions of the drug had sales of about $41.67 million during the 12-month period ending in September, according to IMS Health.

     

  • ZeaVision expands distribution of its EyePromise supplement line

    CHESTERFIELD, Mo. — ZeaVision on Wednesday announced that its EyePromise natural supplements are now available for broader distribution through vitamin, health retail and e-tail channels.

    EyePromise products contain the highest levels of natural zeaxanthin of any eye health supplement, according to ZeaVision. The newest formula, EyePromise vizual EDGE, is based on the success of EyePromise vizual EDGE PRO, popular among professional athletes because it enhances their ability to see objects better and, therefore, react faster.

X
This ad will auto-close in 10 seconds